“We intend to establish Takeda India as a CoE in clinical research”

Japanese multinational pharmaceutical company Takeda announced the appointment of Koki Sato as the Head for the company’s India business on April 1, 2020. Sato has been a part of Takeda since 2003 and has grown within the company to hold various senior international roles across multiple functions, including commercial operations, finance, and HR. Prior to this role, he was the General Manager of Ukraine, Belarus, and Moldova (UBM) Cluster in Takeda’s ICMEA (India, C.I.S., Middle East, Turkey, and Africa) area. BioSpectrum India took this opportunity to interact with Koki Sato, General Manager (GM), Takeda Pharmaceuticals India Pvt. Ltd to find out more about the growth of the India business at Takeda.

Relex Health focuses on medication therapy management

Bengaluru based startup Relex Health recently announced a first-of-its-kind Medication Therapy Management Programme in India.

Building indigenous DIAGNOSTIC CAPABILITIES

India is facing a bigger burden of not having enough diagnostic kits in hand. Specifically, there is a shortage of reagents and consumables required to carry out the diagnostic tests for COVID-19. In order to overcome this burden, India is reaching out to South Korea, USA, Germany and China to arrange for more kits in order to increase the current testing capacity for COVID-19. Although this step might help India to some extent in its current containment plan, the real need can only be fulfilled by accelerating indigenous COVID-19 diagnostics manufacturing.

Emerging Stronger: Bioscience Businesses In And Beyond The War On Covid-19

Despite the COVID crises, according to AIOCD AWACS the Indian Pharma Market registered a surprising growth of 8.9 per cent in March 2020 with some evidence of panic buying in chronic medicines. In the stock market too, pharma stocks have managed to retain investor interest amid deep fall in nearly every other sector. Nifty Pharma, at well over 7400 levels, is up by 20 per cent over the last month, and is showing the promise of crossing its 52-week high in the coming months.

Multiplying Efforts To Beat Covid- 19

The government along with the industry is exploring every other possibility to combat the COVID-19 pandemic whether in the form of vaccines, drugs, diagnostic tests, medical equipment or therapeutic interventions. The major objective is to develop a long term solution by pooling proper resources, sharing knowledge and collaboration.

Time to build Indian Medtech industry to global reckoning

India has built amazing infrastructure of science especially interdisciplinary and translational aspects of biology in the last 15 years despite history of low level of investments both in R&D (0.8 per cent of the GDP) as well as healthcare (1.3 per cent of the GDP). This needs to change not just as a stopgap measure but greater investment, consistently over a longerrange horizon, is important. And there is need to leverage the strengths and find strategic responses to the gaps in a mission mode.

BIOSPECTRUM WEBINAR ON “EXPLORING VARIOUS ASPECTS OF COVID-19”- “Indian economy will take 2-3 years to come back to normal position”

As the number of COVID-19 cases continue to rise all across the globe, healthcare authorities and experts are coming together to identify gaps and work together to accelerate and fund priority research needed to help stop this outbreak and prepare for any future outbreaks. With an aim of exploring the various aspects associated with the COVID-19 pandemic, BioSpectrum India conducted a webinar on April 16,which saw participation of industry experts sharing their views on how can India tackle this outbreak.

A RELIEF OR ADDED THREAT FOR INDIA?

Researchers across the globe have observed that there may be a unique mutation in the viral strain infecting the Indian population. And may be that is the reason why few countries are suffering large numbers of fatalities as compared to India.

“Innovation Is Key To Bring Down Cost Of Car-T Therapy In India”

Bengaluru headquartered Syngene International Limited, a global contract research organization, has announced the commissioning of the first phase of its new R&D centre in Hyderabad.

Top 5 Ways To Tackle The Outbreak

Top 5 Ways To Tackle The Outbreak

“Indian pharma industry likely to reach $100B and medical devices sector reach $50B by 2025”

INDIA PHARMA AND INDIA MEDICAL DEVICE 2020

“Council plans to set up Centres of Excellence”

Established in 2014, Life Sciences Sector Skill Development Council (LSSSDC) is a Non-Statutory Skill Certification Body authorized by Ministry of Skill Development and Entrepreneurship, Government of India.

Marketing with an enticement, not a mallet : content marketing strategies for startups in biotech

Competing against the industry Goliaths that dominate the health and biotech industries can seem like an impossible task for a company in its infancy. Fortunately, small businesses and startups can build a competitive edge by combining innovation with an organized content marketing campaign. Small business owners simply need to be aware of the key challenges they face and combat those challenges through a strategic content marketing campaign aimed at health and biotech customers.

Karnataka to formulate new policy on Science and Technology

The Government of Karnataka is in the process of bringing out a Science and Technology (S&T) Policy, wherein it is proposing many programmes to support R&D in the state.

India proposes COVID-19 emergency fund for SAARC countries

Prime Minister Narendra Modi recently interacted with the leaders of the SAARC countries through video conference to chart out a common strategy in order to combat COVID-19 in the region.

Top 6 Pharma Social Media Break Through in 2019

In a relatively short period of time, social media has reshaped communication for consumers and healthcare professionals alike.

INDIAN PHARMA UNDER USFDA LENS

India holds a major stake in the US market. Hence US Food Drug Administration (FDA) has imposed stringent regulations to meet the international regulatory requirement which further boosts number of inspections carried out at various facilities on Indian pharmaceutical companies. With the booming generics business, USFDA is keeping a sternwatch over the Indian pharma companies to safeguard the health interest of its population. The government of India has been adopting to stringent mechanisms to ensure the quality of drugs into the market. The Ministry of Health has been imposing a mandatory BA/BE studies for all the pharmaceutical manufacturing permissions. Government’s “Make in India” initiative is expected to deliver more safe, efficient and quality drugs into the market. With these and many more initiatives India will continue to be the powerhouse of pharmaceutical industry in coming years.

Era of partial replacement of doctors gaining impetus

Technology is assisting healthcare providers to make phenomenal gains by improving outcome in treatments by accurate diagnosis and treatment of diseases. Experts say that technological advancement in healthcare like adoption of digital pathology is expected to be the topmost choice in the healthcare industry, as it has proven to reduce the workload of physicians and clinicians. Additionally, it has also resulted in squeezing down the patient’s expenses due to more systemic approach in health systems enabled by technological developments.

'We are trying to learn and embrace technology as much as possible'

Novo Nordisk, a global healthcare company has recently appointed Vikrant Shrotriya as its new Managing Director & Corporate Vice President for the India business.

Keeps Your Risk Factors Under Complete Control

Sartorius introduced the very first Sartocheck ® Filter Integrity Tester in 1980 and over a period spanning more than 3 decades, Sartocheck ® Filter Integrity Tester evolved into an extremely sophisticated automated integrity test solution which is preferred by customers across the globe.

Medical devices need separate regulatory framework

Medical devices need separate regulatory framework

IVDs – The next big story after pharma

The Indian In Vitro Diagnostics (IVDs) sector, included under the Make-in-India initiative of the Government of India, has huge market potential and is witnessing double-digit growth.

INDIGENOUS MEDICAL DEVICE AND DIAGNOSTICS MARKET GROWING AT 6% CROSSES RS 36,000 CRORE

The market of indigenous medical device and diagnostics is estimated at Rs 36,400 crore growing at 6 per cent for 2018-19.

Government's Nano approach for pharma industry

Nanotechnology is now known to be the game-changer when it comes dealing with the rising burden of various life-threatening diseases such as cancer, diabetes, cardiovascular diseases along with others.

Diagnostic services in India: an untapped potential

With the second-largest population in the world, India also has a massive disease burden which has barred it from enjoying its demographic dividend optimally.

Digitization Improves Lab Supply Chain Management

Time is a major obstacle for the invention of a new product or for the development of a novel product from basic concepts. The time taken for an idea to be proved, prototyped and developed into beneficial invention determines the success of the product as there are multiple competitors existing in the market. As a result, scientists have to manage their time efficiently while executing their projects. However, unfortunately a lot of time is wasted when the required lab supplies such as reagents, kits, consumables, equipment etc. are not available while conducting crucial research experiments. Scientists often struggle in contacting the right biosuppliers, establishing trust with a new brand of product or facing delays in the delivery of an urgent material.

India Announces Major Tax Cuts To Boost Investment

USV Private Limited, an Indian multinational pharmaceutical, and biotechnology company based in Mumbai reacting quickly to the developments and leveraging on the government’s surprise corporate tax rate cut on September 20 announced that it will proceed with its investment of Rs 400 crore on a new state-of-art formulation plant at Vadodara in Gujarat.

'We Have Developed Over 15000 NCEs This Year'

A leading global Contract Research and Manufacturing Services (CRAMS) company in the area of drug discovery and development, TCG Lifesciences Pvt. Limited started its operations in 2001 in Kolkata and currently has a presence in the United States, Europe, and Japan.

'PPPs, CoEs Are Needed To Practice Precision Diabetes Care'

Roche Diabetes Care India, a pioneer in the development of diabetes management systems and services, has appointed executive from Novo Nordisk, Omar Sherief Mohammad as the new General Manager for its India business.

'India's Life Science And Healthcare Industries Are Some Of The Fastest Growing Sectors'

Promega Biotech India Private Ltd, a 100 per cent subsidiary of Promega Corporation USA started its operation in August 2014 in New Delhi has completed five years.